维普期刊资源整合服务平台（V6.5）

47篇 您的检索式：作者名="AMLER LC"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with Erlotinib 显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，：	1
2	Genomic instability in lp and human malignancies显示文摘	Schwab M Praml C Amler LC	1996	Genes Chromosomes Cancer1996，16，4：	1
3	Mutations in the epidermal growth factor receptor and in K-ras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
4	Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer,fallopian tube cancer,or primary peritoneal cancer显示文摘	Makhija S Amler LC Glenn D		0，，07：	1
5	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small- cell lung cancer treated with chemotherapy alone and in combination with erlotinib 显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
6	Mutations in the epidermal growth factor receptor and in KRAS are pre- dictive and prognostic indicators in patients with non - small- cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，：	1
7	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin 0ncol2005，23，25：	1
8	Mutations in the epidermal growth factor receptor and in KRAS are pre- dictive and prognostic indicators in patients with non- small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib 显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，：	1
9	Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer显示文摘	Makhija S Amler LC Glenn D	2010	J Clin Oncol2010，28，7：	1
10	Mutations in the epidermal growth factor receptor and in K-RAS are predictive and prognostic indicators in patients with nonsmall cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE AmLer LC		0，，25：	1
11	Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R显示文摘	AMLER LC AGUS DB LEDUC C	2000	Cancer Res2000，60，21：	1
12	Clinical activity of gemc-itabine plus pertuzumab in platinum-resistant ovarian cancer,fal-lopian tube cancer,or primary peritoneal cancer显示文摘	Makhija S Amler LC Glenn D	2010	J Clin On-col2010，28，7：	1
13	Mutations in the epider-mal growth factor receptor and in KRAS are predictive and prognosticindicators in patients with non-small-cell lung cancer treated withchemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin On-col2005，23，25：	1
14	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
15	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib 显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
16	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with Erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
17	Secretory type Ⅱ phospholipase A2(PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normalcolonic mucosa显示文摘	Praml C Amler LC Dihlmann S	1998	Oncogene1998，17，15：	1
18	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib 显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1
19	Mutation in the ep-idermal growth factor receptor and in KRAS are predictve andprognostic indication in patients with non-small-cell lung cancertreated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，：	1
20	Mutations in the ep-idermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib显示文摘	Eberhard DA Johnson BE Amler LC	2005	J Clin Oncol2005，23，25：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示